Randomized trial · people
PT-141: +0.7 vs +0.2 satisfying sexual events a month at 12 weeks
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In premenopausal women, the higher PT-141 doses added a small gain in satisfying sexual events over placebo, and nausea, flushing and headache were the side effects that came up.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 327
- Published
- 2016
- Journal
- Womens Health (Lond)
What they tested
The team tested whether bremelanotide (PT-141), used under the skin as needed, works and is safe for premenopausal women with female sexual dysfunctions, and which dose fits best.
How the study was done
A randomized, placebo-controlled dose-finding trial in premenopausal women with female sexual dysfunctions, with 327 women in the efficacy analysis. Women gave themselves a placebo (dummy shot) or PT-141 at 0.75, 1.25 or 1.75 mg under the skin when they chose to, over 12 weeks.

What they found
In the pooled 1.25 and 1.75 mg arms, satisfying sexual events rose by +0.7 a month from the start, compared with +0.2 on placebo (p = 0.0180). The total score on the female sexual function index went up +3.6 versus +1.9 (p = 0.0017). The total score on the female sexual distress scale for desire, arousal and orgasm changed by -11.1 versus -6.8 (p = 0.0014). The side effects named were nausea, flushing and headache.
What it doesn’t show
The trial ran 12 weeks and included only premenopausal women. The main comparison pooled the two higher doses against placebo rather than looking at each dose alone.
The paper
Clayton et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond). 2016.
The compound
More studies on PT-141
- PT-141: side-effect dropouts far higher than placebo in re-analysisMeta-analysis · people · 2021
- PT-141: nausea in 40.0% vs 1.3% on placebo in phase 3 safety dataSystematic review · people · 2022
- Every study on PT-141
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.